The Global Neuroendocrine Carcinoma Treatment market is expected to reach US$ 1.7 billion by 2022, with a CAGR of 8.0% indicating positive market growth over the forecast period.According to Future Market Insights, the market for somatostatin analogues by treatment type is expected to reach US$ 1.0 billion in 2022,.
Neuroendocrine Carcinoma Treatment Market is expected to reach US$ 2.9 Bn by the end of 2029 with sales revenue expected to register CAGR of 8.0% from 2022